Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced castration resistant prostate cancer

Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA
PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced castration resistant prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )
7 Nov 2019

Analysis of assay used in IMpassion130 to guide treatment of metastatic and advanced breast cancers

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Analysis of assay used in IMpassion130 to guide treatment of metastatic and advanced breast cancers ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
31 Oct 2019

Using aspirin for cancer prevention

Prof Ruth Langley - University College London, London, UK
Using aspirin for cancer prevention ( Prof Ruth Langley - University College London, London, UK )
24 Oct 2019

Shaping the future of metastasis - ecancer investigates

Monique Biryiana - ecancer Medical Reporter, Dr Chris Bakal - Dynamical Cell Systems Team Leader, Patricia Pascual Vargas - PhD Student
Shaping the future of metastasis - ecancer investigates ( Monique Biryiana - ecancer Medical Reporter, Dr Chris Bakal - Dynamical Cell Systems Team Leader, Patricia Pascual Vargas - PhD Student )
14 Oct 2019

Comment: Critical quality attributes of biosimilars

Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands
Comment: Critical quality attributes of biosimilars ( Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands )
8 Oct 2019

Simplifying molecular subtypes of metastatic gastric cancer

Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain
Simplifying molecular subtypes of metastatic gastric cancer ( Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain )
8 Oct 2019

VOLFI: FOLFOXIRI and panitumumab in RAS wild-type metastatic colorectal cancer

Dr Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany
VOLFI: FOLFOXIRI and panitumumab in RAS wild-type metastatic colorectal cancer ( Dr Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany )
7 Oct 2019

CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer

Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands
CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer ( Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands )
7 Oct 2019

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer

Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer ( Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain )
7 Oct 2019

CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanoma

Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain
CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanoma ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )
7 Oct 2019

ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma

Dr Jonathan Ledermann - University College Hospital, London, UK
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma ( Dr Jonathan Ledermann - University College Hospital, London, UK )
7 Oct 2019

Checkmate 227: Final analysis for the non small cell lung cancer trial

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
Checkmate 227: Final analysis for the non small cell lung cancer trial ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
7 Oct 2019